Company profile for Editas Medicine

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Editas Medicine is building the leading genome editing company dedicated to treating patients with genetically defined diseases. At Editas Medicine, we believe we have entered a new era in genomic medicine as the growth of genomic information in recent years has significantly expanded our understanding of genetically defined diseases. Furthermore, a new technology known as CRISPR (Clustered Regularly Interspaced Short Palindro...
Editas Medicine is building the leading genome editing company dedicated to treating patients with genetically defined diseases. At Editas Medicine, we believe we have entered a new era in genomic medicine as the growth of genomic information in recent years has significantly expanded our understanding of genetically defined diseases. Furthermore, a new technology known as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has the potential to achieve accurate, directed changes in DNA and fulfill the promise that started with the sequencing of the human genome – the potential to treat diseases at their source.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
11 Hurley Street Cambridge, MA 02141
Telephone
Telephone
617.401.9000
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

Global ChemShow

Not Confirmed

envelop Contact Supplier

Global ChemShow

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/03/3179375/0/en/Editas-Medicine-Announces-EDIT-401-Poster-Presentation-at-the-American-Heart-Association-AHA-Scientific-Sessions-2025.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/10/09/3164355/0/en/Editas-Medicine-Reports-In-Vivo-Proof-of-Concept-Data-for-EDIT-401-at-the-European-Society-of-Gene-and-Cell-Therapy-ESGCT-32nd-Annual-Congress.html

GLOBENEWSWIRE
09 Oct 2025

https://www.prnewswire.com/news-releases/scientific-equipment-goes-to-auction-in-tiger-group-and-equipnet-sale-on-oct-16-302578031.html

PR NEWSWIRE
08 Oct 2025

https://www.globenewswire.com/news-release/2025/10/06/3161769/0/en/Editas-Medicine-Announces-EDIT-401-Oral-Presentation-at-the-European-Society-of-Gene-and-Cell-Therapy-ESGCT-32nd-Annual-Congress-and-Participation-in-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
06 Oct 2025

https://www.fiercebiotech.com/biotech/after-strategic-pivot-editas-lays-out-plan-target-high-cholesterol-gene-editing

FIERCE BIOTECH
02 Sep 2025

https://www.globenewswire.com/news-release/2025/09/02/3142475/0/en/Editas-Medicine-Nominates-EDIT-401-an-LDLR-Targeted-Medicine-as-Lead-In-Vivo-Development-Candidate.html

GLOBENEWSWIRE
02 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty